Morphosys is a biopharmaceutical company founded in 1995 with its headquarters in Martinsried, Germany. It went public on the Frankfurt Stock Exchange in 2000 and is part of the TecDAX stock index. Morphosys has collaborated with several global pharmaceutical companies including Janssen Biotech, Merck, Amgen, Boehringer Ingelheim, and Novartis. It has a market capitalisation of more than €500 million as of November 2022.
Morphosys is engaged in developing and commercialising innovative therapeutic antibodies for the treatment of various diseases with high medical needs. Its lead product candidate, MOR106, is undergoing Phase III clinical trials to treat atopic dermatitis in adults and adolescents. With a strong focus on research and development, Morphosys is well-positioned to remain at the forefront of biotechnology innovation. Investors looking for exposure to biotechnology should consider Morphosys as a potential investment.
Morphosys AG has been on a rollercoaster ride when it comes to its share price since the company's listing in 1999. After reaching a peak of €136.20 per share in Jan 2020, the price dropped significantly during the Covid-19 pandemic, reaching a low of €81.80 in March 2020. Since then, the stock has never rebounded and is now trading around €15-20 per share.
Investors have been cautious of the stock due to its volatile price trend. However, there have also been positive events that could affect the company’s share price going forward. For example, Morphosys has recently announced a new technology partnership with Johnson & Johnson which could lead to improved returns for shareholders. It will be interesting to see if these developments will ultimately lead to a more stable share price for Morphosys. In the meantime, traders should keep an eye on the news and trends relating to the company in order to make informed decisions about their investments.
Morphosys, the German biopharmaceutical company, is a leader in the development of therapeutic antibodies. Its competitors include Incyte Corporation, which has focused primarily on small molecules and gene-targeted therapies; Genmab A/S, which also focuses on antibody therapy development and manufacturing; and Biogen Inc., which specializes in neurological diseases. All of these companies have similar stocks, with prices hovering around $100-$200 depending on the market at any given time.
Morphosys's strengths include its advanced technology platform, which is a cost-effective method for identifying antibodies that can be used to treat various diseases; its broad portfolio of therapeutic antibody candidates; and its extensive collaborations with other biopharmaceutical companies. Its weaknesses include the potential for delays in clinical development and the potential for additional costs associated with manufacturing, which could have an impact on profitability. Additionally, Morphosys faces competition from established competitors who may have already developed treatments in the same therapeutic area.
|Swap long||[[ data.swapLong ]] points|
|Swap short||[[ data.swapShort ]] points|
|Spread min||[[ data.stats.minSpread ]]|
|Spread avg||[[ data.stats.avgSpread ]]|
|Min contract size||[[ data.minVolume ]]|
|Min step size||[[ data.stepVolume ]]|
|Commission and Swap||Commission and Swap|
|Trading Hours||Trading Hours|
* The spreads provided are a reflection of the time-weighted average. Though Skilling attempts to provide competitive spreads during all trading hours, clients should note that these may vary and are susceptible to underlying market conditions. The above is provided for indicative purposes only. Clients are advised to check important news announcements on our Economic Calendar, which may result in the widening of spreads, amongst other instances.
The above spreads are applicable under normal trading conditions. Skilling has the right to amend the above spreads according to market conditions as per the 'Terms and Conditions'.
Why Trade [[data.name]]
Make the most of price fluctuations - no matter what direction the price swings and without capital restrictions that come with buying the underlying asset.